4.6 Article

Human insulin/IGF-1 and familial longevity at middle age

Journal

AGING-US
Volume 1, Issue 8, Pages 714-722

Publisher

IMPACT JOURNALS LLC
DOI: 10.18632/aging.100071

Keywords

familial longevity; height; glucose handling; IGF-1; IGFBP3

Funding

  1. Innovation Oriented research Program on Genomics (SenterNovem) [IGE01014, IGE5007]
  2. Centre for Medical Systems Biology (CMSB)
  3. Netherlands Genomics Initiative/Netherlands Organization for scientific research (NGI/NWO) [05040202, 050-060-810]
  4. EU funded Network of Excellence Lifespan [FP6 036894]
  5. Netherlands Genomics Initiative (NCHA) [050-060-810]

Ask authors/readers for more resources

Recently, we have shown that compared to controls, long-lived familial nonagenarians (mean age: 93.4 years) from the Leiden Longevity Study displayed a lower mortality rate, and their middle-aged offspring displayed a lower prevalence of cardio-metabolic diseases, including diabetes mellitus. The evolutionarily conserved insulin/IGF-1 signaling (IIS) pathway has been implicated in longevity in model organisms, but its relevance for human longevity has generated much controversy. Here, we show that compared to their partners, the offspring of familial nonagenarians displayed similar non-fasted serum levels of IGF-1, IGFBP3 and insulin but lower non-fasted serum levels of glucose, indicating that familial longevity is associated with differences in insulin sensitivity.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available